PharmaMar has requested the process of re-examination for Aplidin ® from the EMA

(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin ® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news